RLMD

Relmada Therapeutics Inc

Sep 16 • 04:00PM ET

1.60

-0.07 -4.19 %

Healthcare • Biotechnology • USA • NASD

Peers: AXSM SAGE ACAD NBIX VKTX ITCI XENE OVID CORT BHVN

Index	-	P/E	-	EPS (ttm)	-2.21	Insider Own	20.34%	Shs Outstand	33.19M	Perf Week	2.56%
Market Cap	53.11M	Forward P/E	-	EPS next Y	-	Insider Trans	22.61%	Shs Float	26.44M	Perf Month	147.64%
Enterprise Value	32.49M	PEG	-	EPS next Q	-0.45	Inst Own	24.88%	Short Float	2.11%	Perf Quarter	125.96%
Income	-67.81M	P/S	-	EPS this Y	27.17%	Inst Trans	80.76%	Short Ratio	0.76	Perf Half Y	442.93%
Sales	0.00M	P/B	3.33	EPS next Y	-	ROA	-147.18%	Short Interest	0.56M	Perf YTD	207.69%
Book/sh	0.48	P/C	2.58	EPS next 5Y	-	ROE	-175.12%	52W High	3.98 -59.80%	Perf Year	-51.07%
Cash/sh	0.62	P/FCF	-	EPS past 3/5Y	28.20% 0.68%	ROIC	-425.15%	52W Low	0.24 565.56%	Perf 3Y	-94.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	16.51% 19.04%	Perf 5Y	-95.71%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	23.17%	Oper. Margin	-	ATR (14)	0.20	Perf 10Y	-95.32%
Dividend Ex-Date	-	Quick Ratio	4.11	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	71.50	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.11	EPS Q/Q	49.51%	SMA20	36.87%	Beta	0.81	Target Price	1.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	90.84%	Rel Volume	3.05	Prev Close	1.67
Employees	17	LT Debt/Eq	0.00	Earnings	Aug 07 AMC	SMA200	169.56%	Avg Volume	730.90K	Price	1.60
IPO	Jun 20, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.78% -	Trades		Volume	2,149,211	Change	-4.19%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-24	Downgrade	Mizuho	Outperform → Neutral	$23 → $1
Sep-17-24	Upgrade	Jefferies	Hold → Buy	$3.50 → $13
Jun-05-24	Downgrade	Goldman	Neutral → Sell	$3 → $2
Oct-14-22	Downgrade	Truist	Buy → Hold	$90 → $10
Oct-14-22	Downgrade	Guggenheim	Buy → Neutral
Oct-14-22	Downgrade	Goldman	Buy → Neutral	$81 → $8
Oct-13-22	Downgrade	Oppenheimer	Outperform → Perform	$64 → $7
Nov-18-21	Initiated	Mizuho	Buy	$50
May-20-21	Resumed	Goldman	Buy	$78
Oct-28-20	Downgrade	Goldman	Buy → Neutral	$69 → $40
Jul-14-20	Initiated	Oppenheimer	Outperform	$75
May-04-20	Initiated	SunTrust	Buy	$75
Apr-21-20	Initiated	Goldman	Buy	$63
Jan-27-20	Initiated	Jefferies	Buy	$75
Jan-10-20	Initiated	SVB Leerink	Outperform	$50
Dec-16-19	Initiated	Guggenheim	Buy	$64

Show Previous Ratings

Sep-16-25 11:20AM	Sidoti Events, LLC's Virtual September Small-Cap Conference (ACCESSWIRE)
09:00AM	Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Sep-10-25 07:15AM	Relmada Issues Mid-Year CEO Letter to Shareholders (GlobeNewswire)
Sep-03-25 04:10PM	Exclusive: Relmada CEO says his recent buy reflects significant undervaluation (Investing.com) -6.80%
Sep-02-25 03:53AM	Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study (Insider Monkey) +26.79%
04:05PM	Loading…
Aug-07-25 04:05PM	Relmada Therapeutics Reports Second Quarter 2025 Financial Results and Announces NDV-01 6-Month Follow-up Safety and Efficacy Data in NMIBC (GlobeNewswire)
Jul-31-25 07:00AM	Relmada Therapeutics to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025 (GlobeNewswire)
Jul-15-25 08:00AM	Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01 (GlobeNewswire)
Jul-09-25 08:00AM	DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors (GlobeNewswire)
Jun-17-25 07:00AM	Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology (GlobeNewswire)
May-13-25 09:08AM	Q1 2025 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:09AM	Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... (GuruFocus.com)
May-12-25 04:01PM	Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -5.05%
May-08-25 07:30AM	Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 (GlobeNewswire) +5.64%
Apr-28-25 01:38PM	Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 (GlobeNewswire) -44.64%
09:00AM	Loading…
Apr-27-25 09:00AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Apr-24-25 08:00AM	Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data (GlobeNewswire) +6.86%
Apr-14-25 08:41AM	UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
07:30AM	Relmada Therapeutics To Present NDV-01 Data at AUA2025 (GlobeNewswire)
Mar-28-25 07:05AM	Q4 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... (GuruFocus.com)
Mar-27-25 08:07PM	Relmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:05PM	Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update (GlobeNewswire)
Mar-26-25 09:00AM	Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 (GlobeNewswire)
Mar-25-25 07:30AM	Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd. (GlobeNewswire) +6.09%
Feb-07-25 06:46AM	Relmada acquires Tourettes therapy rights from Asarina (Pharmaceutical Technology) -9.62%
Feb-06-25 07:30AM	Relmada Therapeutics Acquires Potential Therapy for Tourette Syndrome from Asarina Pharma AB (GlobeNewswire) -10.00%
Dec-09-24 07:30AM	Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017 (GlobeNewswire) +5.14%
Dec-05-24 07:36AM	Relmada reports DMC assessment indicates Phase 3 Reliance II trial is futile (TipRanks) -28.57%
Dec-04-24 07:30AM	Relmada Therapeutics Reports That Data Monitoring Committee (DMC) Assessment Indicates That the Phase 3 Reliance II Trial is Futile at its Interim Analysis and is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance (GlobeNewswire) -77.26%
09:00AM	Loading…
Nov-19-24 09:00AM	Relmada Therapeutics to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-14-24 07:30AM	Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease (GlobeNewswire)
Nov-10-24 09:02PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 11-11-2024 (Market Exclusive)
Nov-08-24 02:28AM	Relmada Therapeutics Inc (RLMD) Q3 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com)
Nov-07-24 04:32PM	Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Nov-04-24 04:30PM	Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Sep-12-24 01:07AM	Insider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD) (GuruFocus.com) +8.28%
01:06AM	Relmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 Shares (GuruFocus.com)
Aug-12-24 09:35AM	Relmada Therapeutics (RLMD) Loses -43.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-08-24 01:51PM	Q2 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -29.01%
Aug-07-24 04:05PM	Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-05-24 07:30AM	Relmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire) -5.83%
Jun-18-24 08:30AM	Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry (PR Newswire)
Jun-10-24 07:30AM	Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire) +5.76%
Jun-03-24 07:30AM	Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference (PR Newswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-11-24 08:41AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 06:20AM	Q1 2024 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:40AM	Relmada Therapeutics Inc (RLMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-08-24 09:55PM	RLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
May-06-24 07:30AM	Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 (PR Newswire)
Mar-20-24 10:27AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript (Insider Monkey) -17.41%
06:27AM	Q4 2023 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:52PM	RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
05:31PM	Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results (GuruFocus.com)
04:15PM	Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results (PR Newswire)
Mar-12-24 07:30AM	Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 (PR Newswire)
Mar-05-24 07:30AM	Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (PR Newswire)
Feb-01-24 03:02PM	Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares (GuruFocus.com) +16.03%
Jan-05-24 05:12PM	Health Care Roundup: Market Talk (The Wall Street Journal) +7.27%
Jan-04-24 07:30AM	Relmada Therapeutics Provides Corporate Update (PR Newswire) -31.68%
Dec-29-23 08:47AM	11 Best Psychedelic Stocks to Buy in 2024 (Insider Monkey) +9.23%
Dec-20-23 02:39PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (ready to review) (Insider Monkey)
02:14PM	5 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey)
Nov-10-23 01:57PM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 06:47PM	Relmada Therapeutics Inc (RLMD) Reports Third Quarter 2023 Financial Results (GuruFocus.com)
04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results (PR Newswire)
Nov-03-23 07:30AM	Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023 (PR Newswire)
Oct-11-23 08:31AM	Relmada Therapeutics to Present New Preclinical Data on its Psilocybin Program at AASLD The Liver Meeting 2023 (PR Newswire)
Oct-09-23 07:30AM	Relmada Therapeutics to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit (PR Newswire)
Oct-06-23 07:30AM	Relmada Therapeutics to Present Data from its REL-1017 and Psilocybin Programs at the 36th European College of Neuropsychopharmacology (ECNP) Congress (PR Newswire)
Sep-20-23 08:30AM	Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressive Disorder (PR Newswire) +6.09%
Aug-23-23 07:30AM	Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder (PR Newswire)
Aug-08-23 04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results (PR Newswire) +7.09%
Aug-01-23 07:30AM	Relmada Therapeutics to Report Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 8, 2023 (PR Newswire)
Jul-31-23 06:10AM	7 Healthcare Stocks to Ditch Before They Make Your Portfolio Sick (InvestorPlace)
Jun-08-23 07:30AM	Relmada Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference (PR Newswire)
Jun-02-23 07:30AM	Relmada Therapeutics to Participate in the 2023 Jefferies Global Healthcare Conference (PR Newswire)
May-24-23 07:42AM	Relmada Therapeutics Insider Ups Holding By 62% During Year \ (Simply Wall St.)
07:30AM	Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2023 Annual Meeting (PR Newswire)
May-11-23 04:01PM	Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (PR Newswire) -6.31%
May-08-23 07:30AM	Relmada Therapeutics to Report First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11, 2023 (PR Newswire) +9.94%
Apr-12-23 12:59PM	Will Relmada Therapeutics (NASDAQ:RLMD) Spend Its Cash Wisely? (Simply Wall St.)
Mar-27-23 07:12AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-24-23 09:08AM	Q4 2022 Relmada Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-23-23 04:01PM	Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results (PR Newswire)
Mar-17-23 08:30AM	Relmada Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 23, 2023 (PR Newswire) -5.36%
Feb-27-23 09:13AM	10 Most Promising Psychedelic Stocks According To Analysts (Insider Monkey)
Feb-17-23 06:35AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) is favoured by institutional owners who hold 52% of the company (Simply Wall St.)
Jan-12-23 08:00AM	Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments to its Board of Directors (PR Newswire) +15.30%
Jan-09-23 08:00AM	Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer (PR Newswire)
Dec-29-22 09:11AM	Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2022 Earnings Call Transcript (Insider Monkey) +10.94%
Dec-15-22 06:08AM	Sergio Traversa Is The CEO & Director of Relmada Therapeutics, Inc. (NASDAQ:RLMD) And They Just Picked Up 62% More Shares (Simply Wall St.)
Dec-08-22 08:39AM	Relmada Therapeutics shares decline 40% on Thursday (MarketWatch) -47.84%
08:12AM	Relmada Shares Nosedive As Another Depression Trial Goes Up In Smoke (Benzinga)
Dec-07-22 04:05PM	Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (PR Newswire)
Nov-10-22 04:05PM	Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results (PR Newswire) +8.73%
Nov-08-22 04:15PM	Relmada Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 10, 2022 (PR Newswire)
Nov-03-22 12:24PM	We Think Relmada Therapeutics (NASDAQ:RLMD) Needs To Drive Business Growth Carefully (Simply Wall St.) +5.18%

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TRAVERSA SERGIO	Chief Executive Officer	Aug 27 '25	Buy	0.67	129,455	86,735	944,024	Aug 28 04:56 PM
TRAVERSA SERGIO	Chief Executive Officer	Aug 26 '25	Buy	0.62	80,545	49,938	814,569	Aug 28 04:56 PM
TRAVERSA SERGIO	Chief Executive Officer	Aug 28 '25	Buy	0.74	55,976	41,422	1,000,000	Aug 28 04:56 PM
Kelly Paul Edward	Chief Operating Officer	May 16 '25	Buy	0.43	200,000	86,060	412,295	May 20 06:03 PM
Shenouda Maged	Chief Financial Officer	May 19 '25	Buy	0.49	90,000	43,686	228,335	May 20 06:03 PM
Shenouda Maged	Chief Financial Officer	May 20 '25	Buy	0.52	60,000	31,422	288,335	May 20 06:03 PM
Shenouda Maged	Chief Financial Officer	May 16 '25	Buy	0.44	50,000	22,100	138,335	May 20 06:03 PM
Ence Chuck	CA and CO	May 16 '25	Buy	0.45	228,961	103,330	267,931	May 20 06:02 PM
TRAVERSA SERGIO	Chief Executive Officer	May 20 '25	Buy	0.56	147,686	82,246	734,024	May 20 06:01 PM
TRAVERSA SERGIO	Chief Executive Officer	May 16 '25	Buy	0.45	172,314	77,472	556,338	May 20 06:01 PM
TRAVERSA SERGIO	Chief Executive Officer	May 19 '25	Buy	0.50	30,000	14,994	586,338	May 20 06:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RLMD

Relmada Therapeutics Inc

Upgrade your FINVIZ experience